Browsing by Author "Reyes, Felipe"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile
    (2023) Le Corre, Nicole; Abarca, Katia; Astudillo, Patricio; Potin, Marcela; López, Sofía; Goldsack, Macarena; Valenzuela, Vania; Schilling Redlich, Andrea; Gaete, Victoria; Rubio, Lilian; Calvo, Mario; Twele, Loreto; González, Marcela; Fuentes, Daniela; Gutiérrez, Valentina; Reyes, Felipe; Tapia, Lorena I.; Villena, Rodolfo; Retamal-Díaz, Angello; Cárdenas, Antonio; Alarcón-Bustamante, Eduardo; Meng, Xing; Xin, Qianqian; González-Aramundiz, José V.; Alvarez-Figueroa, María Javiera; González, Pablo A.; Bueno, Susan M.; Soto, Jorge A.; on behalf of the PedCoronaVac03CL Study Group; Perret, Cecilia; Kalergis, Alexis M.
    During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.
  • Thumbnail Image
    Publication
    Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
    (2022) Escobar, Alejandro; Reyes, Felipe; Acevedo, Mónica; Alonso, Luis; Valiente, Fernando; Soto, Ricardo; Portillo, Hugo; Gatica, Jimena; Flores, Iván; Nova, Estefanía; Barrera, Carlos; Bono, María; Vargas, Leonardo; Simon, Valeska; Leiva, Elias; Vial, Cecilia; Hormazábal, Juan; Jimena, Lina; Valdés, Daniel; Sandino, Ana; Imarai, Mónica; Acuña, Claudio
    CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
  • Thumbnail Image
    Item
    Evaluation of three laboratory methods diagnostic sensitivity in influenza A infection: RIDT, DFA and DFA with cytocentrifugation versus RT-PCR
    (Sociedad Chilena de Infectologia, 2014) Wilhelm, Jan; Yubero, Joao; Fuentes, Constanza; Ríos, Paulina; Leyton, Oscar; Reyes, Felipe
    The specific diagnosis of influenza A infection makes it possible to control its spread, decreases the unnecessary use of antibiotics, clinical procedures and laboratory test, and allows early recognition of outbreaks. Different technologies are currently available in Chile for this purpose. Objective: The study presented here compares the sensitivity for influenza A virus detection of immunocromatography (RIDT), direct fluorescent antibodies-DFA and DFA with cytocentrifugation against the gold standard, RT-PCR. Material and Methods: In 175 nasal swab samples influenza A RIDT and RT-PCR were performed. Another 1689 nasal swab samples were tested by DFA and RT-PCR for influenza A. Finally, 29 nasal swab samples confirmed as Influenza A positive by RT-PCR were tested by DFA with cytocentrifugation. Results: The RIDT, DFA and DFA + cytocentrifugation sensitivity was 47,3%, 57,2% and 72,4%, respectively. Discussion and Conclusion: Their lower cost and faster turnaround time when compared to PCR make RIDT and DFA the tests of choice in diagnostic laboratories in Chile. However, their low sensitivity and NPV, especially during low season, makes more sensitive diagnostic tools necessary to confirm the results. In our study cytocentrifugation increased DFA sensitivity from 57% to 72%.
  • Thumbnail Image
    Item
    Modelo computacional interactivo, semi-automatizado y de código abierto aplicado a la vigilancia de virus respiratorios
    (2020) Reyes, Felipe; Ferrés, Marcela; Vial, Pablo; Vollrath, Valeska; Camponovo, Rossanna; Montecinos, Luisa; Hirsch, Tamara; Valenzuela, Patricia; Perret, Cecilia
    Las infecciones respiratorias agudas (IRA) causadas por virus son una importante causa de morbilidad y mortalidad en el mundo, afectando principalmente a niños y adultos mayores. Se asocian a un alto número de consultas y hospitalizaciones, a una significativa sobrecarga del sistema de salud y a un alto costo económico. La vigilancia de virus respiratorios tiene el potencial de ayudar a optimizar la respuesta sanitaria, garantizar la disponibilidad de recursos humanos, racionalizar los recursos y disminuir los costos asociados a la atención en salud. Con el objetivo de optimizar la recolección y visualización de los datos de nuestro actual sistema de vigilancia de virus respiratorios, se diseñó una plataforma basada en R y sus paquetes Shiny, que permite la creación de una interfase web interactiva y amigable para la recolección, análisis y publicación de los datos. Se ingresaron a esta plataforma los datos de la red de vigilancia metropolitana de virus respiratorios disponibles desde 2006. En esta plataforma, el investigador demora menos de un minuto en registrar los datos. El análisis y publicación es inmediato, llegando a cualquier usuario con un dispositivo conectado a Internet, quien puede elegir las variables a consultar. Con un costo muy bajo, en poco tiempo y utilizando el lenguaje de programación R, se logró crear un sistema simple e interactivo, disminuyendo el tiempo de carga y análisis de datos de forma considerable, posiblemente aumentando el impacto y la disponibilidad de esta vigilancia

Implementado por OpenGeek Services